about
Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritisRheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review.Gluten-free diet in nonceliac disease.Effect of Erythrina variegata seed extract on hyperlipidemia elicited by high-fat diet in wistar ratsCardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatmentThe role of endothelial cell dysfunction in the cardiovascular mortality of RA.IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAtherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled studyPattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis.Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease.Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritisCells of the synovium in rheumatoid arthritis. Dendritic cells.Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study.Comorbidity profile among patients with rheumatoid arthritis and the impact on prescriptions trend.Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension.The swollen joint, the thickened artery, and the smoking gun: tobacco exposure, citrullination and rheumatoid arthritis.New drug discovery strategies for rheumatoid arthritis: a niche for nonhuman primate models to address systemic complications in inflammatory arthritis.Novel mechanisms of action of the biologicals in rheumatic diseases.Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis.Lack of an association of GNB3 C825T polymorphism and blood pressure in patients with rheumatoid arthritis.Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis.Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis.Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis.Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.The frequency of metabolic syndrome in women with rheumatoid arthritis and in controls.Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?
P2860
Q26783956-15E65087-A601-469C-BC83-EB48BBBFDCDEQ33307666-4C93AF8E-F2DE-49BD-9BA2-816D32D2414FQ34185602-A90556CA-1AFF-4A57-9ADD-FE2CDFE2E1BAQ34373858-B8B6BB5A-41E1-44C7-A5F6-7C1DB087D476Q34563216-07B4A3AE-A799-4624-A9E3-7AAC2BE995CEQ34790008-90957310-BD9A-4C27-9C29-1BF4A7C17206Q34795777-4BFDE47B-D0F6-439A-8581-27178A9C54A3Q34897630-A3A4741C-D33A-4A90-8D24-81C325236738Q35236926-33B36D87-BF4E-4A7D-99C6-11B567E7B39BQ35554016-CAE234EB-42F4-4AA8-AA94-9F98FCCBB56BQ35869041-051AFC37-0601-4D7C-9057-D343D0F8AAC5Q36392394-6094D05E-75F9-4608-92A5-56E8A8827156Q36757006-079AEA39-FD50-4B59-AF21-9CB8ED98CA62Q36758324-6E3257E3-280D-4487-AB5C-09B321927663Q37129611-B84D031D-3056-495A-9ECD-28A4693AAD3CQ37642747-5FA04988-EB3C-4ADE-8A61-EBDD3AB9B325Q37817050-FE9FE92D-3388-4468-B20F-EC935493B79EQ37998089-6A244ECC-4CB8-4A65-B34C-80157E71BEFCQ38076350-2E5F05E7-AE22-4270-BED2-B91668115950Q40525673-36B5AF90-9801-4DE3-80C4-8E329CC90FBAQ44438694-E9ADC3E5-F903-4418-9D7D-42D18E28E3AAQ45129671-33EE4E81-D8BD-44BD-A3FF-8E69EDDFCC6EQ46111865-E4750FA3-E61B-4CAE-BFE2-092081F35E2DQ46337002-52182F88-0831-4B23-B231-FE9A91ACF17AQ50701881-7939CF16-4012-4482-8F24-55BEDAD8869AQ51369900-9CB1A1D4-224C-4D89-999E-9E97D99AE346Q51673816-563C8A01-2752-4F62-ABBF-3D15A9873F8A
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Dyslipidemia and rheumatoid arthritis.
@ast
Dyslipidemia and rheumatoid arthritis.
@en
type
label
Dyslipidemia and rheumatoid arthritis.
@ast
Dyslipidemia and rheumatoid arthritis.
@en
prefLabel
Dyslipidemia and rheumatoid arthritis.
@ast
Dyslipidemia and rheumatoid arthritis.
@en
P2860
P356
P1476
Dyslipidemia and rheumatoid arthritis.
@en
P2093
Situnayake RD
P2860
P304
P356
10.1136/ARD.56.6.341
P407
P577
1997-06-01T00:00:00Z